Faron Pharmaceuticals Oy (4FR.F)

1.8260 -0.0320 (-1.72%) As of 08:20AM CEST. Market open.

Faron Pharmaceuticals Oy

Joukahaisenkatu 6 B
Turku 20520
Finland
358 2469 5151
https://www.faron.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 34

Key Executives

Name	Title	Pay	Exercised	Year Born
Mr. Yrjö Erik Kristian Wichmann M.Sc (Econ.), M.Sc.	Interim Chief Financial Officer	455.09k	N/A	1958
Dr. Maija Hollmen Ph.D.	Chief Scientific Officer	N/A	N/A	N/A
Mr. Vesa Karvonen L.L.M.	General Counsel	N/A	N/A	1972
Ms. Jennifer Smith-Parker	Head of Communications	N/A	N/A	N/A
Dr. Juhana Heinonen	Chief Commercial Officer	N/A	N/A	N/A
Dr. Birge Berns M.D.	Interim Chief Medical Officer	N/A	N/A	N/A

Amounts are as of December 31, 2019 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.

Description

Faron Pharmaceuticals Oy operates as a clinical stage drug discovery and development company. The company's lead product candidates are Traumakine, an investigational intravenous interferon beta-1a therapy for the prevention from cytokine release syndrome (CRS), or ischemia and hyperinflammatory conditions; and Bexmarilimab, a novel anti-Clever-1 humanized antibody that targets a subpopulation of tumor-associated macrophages and converts the highly immunosuppressive M2-like macrophages to a pro-inflammatory state to promote immune activation. The company is also developing bexmarilimab, which is in phase 2 clinical trial for indications of solid tumors; and in phase 1 clinical trial for indications of acute myeloid leukemia and myelodysplastic syndromes. In addition, it develops interferon beta-1a to prevent toxicities from CAR-T therapy in phase 2 clinical trial; and AOC3 inhibitor, which is in preclinical studies for indications of chemotherapy-induced neutropenia. Further, it develops Haematokine, an investigational AOC3 protein inhibitor that is used for regenerative medicines in hematological malignancies, as well as chemotherapy induced suppression of the bone marrow. Faron Pharmaceuticals Oy was founded in 2003 and is headquartered in Turku, Finland.

Corporate Governance

Faron Pharmaceuticals Oy’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.